Table 1.
Baseline characteristics
| All patients n = 37 | EGPAa n = 22 | GPAa n = 15 | |
|---|---|---|---|
| Age (yrs) | 55 ± 16 | 54 ± 16 | 55 ± 16 |
| Gender (male) | 13 (35%) | 5 (23%) | 8 (53%) |
| Cardiovascular risk factors | |||
| Diabetes | 7 (19%) | 5 (23%) | 2 (13%) |
| Hypertension | 13 (35%) | 8 (36%) | 5 (33%) |
| Smokingb | 13 (35%) | 7 (32%) | 6 (40%) |
| Hyperlipidemia | 6 (16%) | 5 (23%) | 1 (7%) |
| Family history of CVD | 11 (30%) | 8 (36%) | 3 (20%) |
| Obesity (BMI ≥ 30 kg/m2) | 9 (24%) | 5 (23%) | 4 (27%) |
| Symptoms (multiple possible) | |||
| Angina | 6 (16%) | 4 (18%) | 2 (13%) |
| Dyspnea | 16 (43%) | 12 (54%) | 4 (27%) |
| Palpitations | 4 (11%) | 4 (18%) | - |
| Syncope | 1 (3%) | 1 (5%) | - |
| ECG abnormality | 11 (30%) | 9 (41%) | 2 (13%) |
| Years since diagnosis | |||
| 3 (0–11) | 4 (0–11) | 2 (0–11) | |
| < 1 | 12 (32%) | 6 (27%) | 6 (40%) |
| 1–4 | 11 (30%) | 5 (23%) | 6 (40%) |
| 5–9 | 11 (30%) | 10 (46%) | 1 (7%) |
| ≥ 10 | 3 (8%) | 1 (5%) | 2 (13%) |
| Disease Activity | |||
| BVAS | 5.5 (1–14) | 5 (3–8) | 11.5 (0–24) |
| Hematocrit | 0.39 (0.36–0.42) | 0.4 (0.38–0.42) | 0.38 (0.32–0.42) |
| Medication | |||
| Beta-blockers | 9 (24%) | 6 (27%) | 3 (20%) |
| ARB | 14 (38%) | 7 (32%) | 7 (47%) |
| ASA | 5 (14%) | 5 (23%) | - |
| CCB | 8 (22%) | 4 (18%) | 4 (27%) |
| Statins | 3 (8%) | 2 (9%) | 1 (7%) |
| Diuretics | 8 (22%) | 7 (32%) | 1 (7%) |
| Steroids | 37 (100%) | 22 (100%) | 15 (100%) |
| NSAID | 1 (3%) | 1 (5%) | - |
| Antibodies | 2 (5%) | 1 (5%) | 1 (7%) |
| Cyclophosphamide | 17 (46%) | 4 (18%) | 13 (87%) |
| Azathioprine | 4 (11%) | 2 (9%) | 2 (13%) |
| Methotrexate | 5 (14%) | 4 (18%) | 1 (7%) |
All values are n (%) or mean ± SD or interquartile ranges. apercentages based on number of EGPA/GPA patients, respectively, bcurrent or ever-smokers. EGPA eosinophilic granulomatosis with polyangiitis, GPA granulomatosis with polyangiitis, CVD cardiovascular disease, BMI body mass index, ECG electrocardiogram, BVAS Birmingham vasculitis activity score, ARB angiotensin receptor blockers, ASA acetylsalicylic acid, CCB calcium channel blockers, NSAID nonsteroidal anti-inflammatory drug